國立高雄大學圖資館 |

Language: English

Back

Histone deacetylase inhibitors in co...

Ganai, Shabir Ahmad.

Histone deacetylase inhibitors in combinatorial anticancer therapy

Record Type:	Electronic resources : Monograph/item
Title/Author:	Histone deacetylase inhibitors in combinatorial anticancer therapyby Shabir Ahmad Ganai.
Author:	Ganai, Shabir Ahmad.
Published:	Singapore :Springer Singapore :2020.
Description:	xvii, 258 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Histone deacetylaseInhibitors.
Online resource:	https://doi.org/10.1007/978-981-15-8179-3
ISBN:	9789811581793$q(electronic bk.)

Histone deacetylase inhibitors in combinatorial anticancer therapy
Ganai, Shabir Ahmad.

Histone deacetylase inhibitors in combinatorial anticancer therapy[electronic resource] /by Shabir Ahmad Ganai. - Singapore :Springer Singapore :2020. - xvii, 258 p. :ill. (some col.), digital ;24 cm.

Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs) -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. -Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions.

ISBN: 9789811581793$q(electronic bk.)

Standard No.: 10.1007/978-981-15-8179-3doiSubjects--Topical Terms:

878079
Histone deacetylase
--Inhibitors.

LC Class. No.: QP552.H5

Dewey Class. No.: 572.66

Histone deacetylase inhibitors in combinatorial anticancer therapy
LDR:02274nmm a2200313 a 4500 001 589275
003 DE-He213
005 20210224155503.0
006 m d
007 cr nn 008maaau
008 210601s2020 si s 0 eng d
020 $a 9789811581793$q(electronic bk.)
020 $a 9789811581786$q(paper)
024 7 $a 10.1007/978-981-15-8179-3 $2 doi
035 $a 978-981-15-8179-3
040 $a GP $c GP
041 0 $a eng
050 4 $a QP552.H5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 572.66 $2 23
090 $a QP552.H5 $b G195 2020
100 1 $a Ganai, Shabir Ahmad. $3 878078
245 1 0 $a Histone deacetylase inhibitors in combinatorial anticancer therapy $h [electronic resource] / $c by Shabir Ahmad Ganai.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2020.
300 $a xvii, 258 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs) -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. -Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions.
650 0 $a Histone deacetylase $x Inhibitors. $3 878079
650 0 $a Cancer $x Treatment. $3 252269
650 0 $a Cancer $x Research. $3 341951
650 0 $a Gene expression. $3 188888
650 0 $a Medical genetics. $3 194842
650 0 $a Nucleic acids. $3 194925
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Gene Expression. $3 220379
650 2 4 $a Gene Function. $3 456568
650 2 4 $a Nucleic Acid Chemistry. $3 376665
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-15-8179-3
950 $a Biomedical and Life Sciences (SpringerNature-11642)